Scalable Solutions for Drug Development

1. Copyright © 2020 Covance. All Rights Reserved.
Scalable Solutions for Drug Development
Partnership That Works™
•April 2020

2. Covance: $4.5B Research & Development Partner
| Confidential2
DEVELOPMENT COMMERCIALIZATIONDISCOVERY
Research Preclinical Phase l Phase ll Phase lll Phase lV RWE
Toxicology
and DMPK
Phase I-IV
Services
Central
Laboratory
Biomarkers
and CDx
Market
Access
Bioanalytical
Services
25,000+ Employees Worldwide Covance SupportedExtensive TA Experience*
Oncology
iiGM
CVMER
NOW
Other
~11,100 Americas
~8,700 EU/MEA
~5,600 APAC
~1,500 MDs & PhDs
• All Top 50 of best selling drugs on
the market in 2018-19
• 90% of the novel Oncology drugs
approved by the FDA in last 5 years
• 55 of the 59 drugs approved by the
FDA in 2018.
11%
7%
19%
21%
43%

3. A Suite of Solutions Designed Around You®
•DRUG DEVELOPMENT & MEDICAL DEVICE SERVICES
3
► Data Management
► Biostatistics &
Programming
► CDISC/SDTM
► Pharmacovigilance
► Medical Writing
► Medical Affairs & RWE
► North America
► Latin America
► Western Europe
► Eastern Europe
► Asia Pacific
► Governance
► Quality
► Finance
► Dedicated Recruiting
► Global Systems
► Early Development
► Central Labs
► Feasibility
► Protocol Design
► Patient Recruitment
► Monitoring
► Study Management
Services
Technology Agnostic
Global Infrastructure
| Confidential

4. Flexible & Scalable Operational Delivery Model
Designed Around the Client
| Confidential4
Flexible Customized Delivery Model
Hybrid
Functional
Service
Full
Service
Global Alliance Lead
Legal
Finances
Human Resources
Quality
Training
Recruitment
Functional Technical Teams/
Local offices/Hubs
Therapeutic Expertise
Late Phase Solutions
Decentralized Trials
Business Operations Lead

5. Covance Has an Extensive Global Footprint
Gain Global Scale To Accelerate Your Trial Enrollment
| Confidential5
25,000+ Employees Worldwide
The
Americas
~11,100
Phase IV:
1,100
Europe,
Middle East
& Africa
~8,700
Phase IV:
1,500
Asia
Pacific
~5,600
Phase IV:
~850
~1,500 MDs & PhDs
* Covance staff data – Aug 2019.

6. 5%
66%
29% Retrospective
Prospective
Observational
Interventional
Global Study Experience – Phase IV Solutions
5-Year Summary
| Confidential6
230
Studies
Data source: 5 year data - 2014-2018 Covance internal metrics
*Clinical trials completed for Biotechs, as percent of all client segments
(Segments = Top 40 Pharma, Biotech, Medical Device, Other)
Sites: 7,962
Patients: 162,899
Countries: 63
Biotech: 32%
Studies By Design
52% 29% 18%
Americas EU APAC
Percentage By Region
17%
17%
16%
13%
11%
6%
6%
6%
4% 4%
Top 10 Therapeutic Areas
Cardiovascular
(16%)
Endocrinology and
Metabolism
(16%)
Neuroscience
(14%)
Oncology
(13%)
Dermatology
(7%)
Gastroenterology
and Hepatology
(6%)
Infectious Disease
(6%)
Hematology
(6%)
Respiratory (7%)
Immunology
(9%)

7. Covance
Global
Global Study Experience – Phase IV Solutions
5-Year Experience That Brings Fresh Insights To Your Strategy
| Confidential7
75+ Global Clinical Facilities
5 Central Lab Facilities
25,400 Global staff
3,350 Central Labs staff
15k+ lab samples
analyzed daily
Data source: 2014-2018 Covance internal metrics
*Staff counts: 2019 HR staff metrics
Study Type
Registry 39
Device 33
Natural History 15
PASS 9
Expanded Access 7
Virtual 4
Rare Disease 71
Clinical
230 Studies
63 Countries
7,962 Sites
162,899 Patients

8. Site Management Center in US & EU
Triage Issues to Project Team &
Facilitate Resolution
Collaborate with on site CRA
Identify Potential Sites
Requiring On-site Visit
Identify potential quality/
compliance challenges &
provide solutions
Site Management Centre (SMC)
Site
Monitor & facilitate on time Data
Collection
Motivate / (Re)train Sites
Site Identification / Qualification
Critical Document
Collection & IRB/EC
Submissions
Site Initiation & Activation
Remote Site Monitoring
Query resolution
Remote / Hybrid Site Close-Out
External Site Management
One stop shop for site study
admin – CTMS & eTMF
Internal Site Management
| Confidential8

9. Data Management and EDC
Covance offers a full set of
EDC services in accordance
with your needs.
Our Partners:
Data quality and quantity scalable to your needs
| Confidential9
THERAPEUTIC
EXPERTISE
► Case report form
(CRF) aligned to
indication
► Efficiencies gained
by referencing
pages from pivotal
trials
► Vendor data
reconciliation for
key data
DATA COLLECTION
► Aligned to research goals
► Confirm safety tracking
► Lessons learned from
previous projects
Ensuring
Data Quality
in
accordance
with your
needs
QUERY
► Customized Data Cleaning
► In-house Data Review
EDC SYSTEM
► Leaner pricing algorithms for Medical Affairs research
► Simple & intuitive interface
► Covance RAVE database builders have highest level
of expertise certification

10. Therapeutic Area Studies Sites Patients
Bone & Joint Disease 100 2,171 14,366
Cardiovascular 197 7,892 119,310
Dermatology 111 1,589 18,029
Endocrinology and Metabolism 225 4,823 56,236
Gastroenterology and Hepatology 142 3,884 31,855
General Medicine 21 51 492
Hematology 70 363 3,394
Immunology 50 383 2,193
Infectious Disease 171 2,912 51,797
Multiple 276 * *
Nephrology 61 1,469 7,592
Neuroscience 285 6,140 66,980
Oncology 960 18,388 102,372
Ophthalmology 96 1,751 10,357
Otolaryngology 11 262 4,238
Pharmacology 237 271 5,688
Pulmonary / Respiratory 167 4,116 38,793
Urogenital 30 1,240 6,576
Women's Health 45 1,774 51,932
Total 3,255 59,479 592,200
Clinical Experience for Your Therapeutic Area
5-year Summary
| Confidential10
* Data reflects in-progress trials running between Jan. 2014 – Dec. 2018. It includes combined
experience of Covance and Chiltern for standalone, full service clinical trial management and
functional service provision experience for Phases I-IV.

11. Copyright © 2020 Covance. All Rights Reserved.
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research
services to the drug, medical device and diagnostics, crop protection and chemical industries. COVANCE is a registered
trademark and the marketing name for Covance Inc. and its subsidiaries around the world.
www.covance.com
Thank You